Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value

Core Viewpoint - Exousia Pro, Inc. has successfully settled litigation with a former Director, marking a significant financial milestone that enhances shareholder value and strengthens the company's balance sheet [1]. Financial Impact - The settlement involves a one-time payment of $147,500, expected to close within 30 days, which will lead to favorable financial restructuring outcomes for the company [2]. - The settlement triggers the cancellation of a $200,000 promissory note and the remaining balance on a note tied to Preferred Stock, significantly reducing debt and improving cash flow [7]. - The agreement also results in the cancellation and return of 6,297,511 shares of Common Stock to treasury, reversing prior dilution and increasing equity value and earnings-per-share potential for current shareholders [7]. Operational Focus - With the resolution of the litigation, Exousia Pro's management can concentrate on advancing its clinical pipeline and expanding telehealth initiatives without the burden of ongoing legal disputes [3]. Company Overview - Exousia Pro, Inc. is a biotechnology company specializing in exosome-based delivery systems for therapeutic and diagnostic applications, aiming to enhance patient access through its telehealth division [4]. Audit and Transparency - The settlement allows for a clean audit under Generally Accepted Accounting Principles (GAAP), enhancing financial transparency and reinforcing confidence among investors [7].